Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX002 · 2 trials · 1 indication
maximum concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| PRX002 | EXPERIMENTAL | PRX002 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PRX002 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Idiopathic Parkinson's disease, Hoehn and Yahr 1-3 * Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs * Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception * Male subjects and their partners of childbearin...
PRX002 is an investigational small molecule being developed for the treatment of Parkinson's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in healthy subjects and one in patients with Parkinson's Disease.
PRX002 is being developed by Prothena Corporation plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol PRTA. The company is conducting clinical trials for this investigational drug in the United States.
PRX002 is in Phase 1 clinical development. Two Phase 1 trials have been completed, including a single ascending dose study in healthy subjects and a multiple ascending dose study in patients with Parkinson's Disease. The drug is investigational and has not received FDA approval.
PRX002 has completed two Phase 1 clinical trials. The first, NCT02095171, was a single ascending dose study in 40 healthy subjects. The second, NCT02157714, was a multiple ascending dose study in 64 patients with Parkinson's Disease. Both trials were conducted in the United States.
PRX002 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. Two Phase 1 trials have been completed, but the drug has not yet progressed to later-stage trials or received regulatory approval for the treatment of Parkinson's Disease.